Insulin Cost Reduction Act: Ending Hidden Rebates for Medicare Patients
This bill aims to lower insulin costs for Medicare beneficiaries by prohibiting hidden price concessions that were not passed on to patients. It mandates that any negotiated discounts on insulin must directly benefit the patient at the point of sale, either at pharmacies or through mail order. This should result in lower out-of-pocket expenses for insulin.
Key points
Prohibits hidden price concessions on insulin drugs under Medicare Part D, aiming to reduce patient costs.
Insurers must pass on all negotiated insulin discounts directly to patients at the point of sale.
Changes will take effect 180 days after enactment, allowing time for implementation.
Expired
Citizen Poll